New York, New York - July 9, 2012 - Investorideas.com, an investor
research portal specializing in sector research including biotech and
pharma stocks, issues a report on biotech companies targeting aggressive
forms of cancer; Roche's (
SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug and Sunshine Biopharma Inc. (
OTCBB: SBFM) with its lead compound, Adva-27a.
Roche is the largest biotech company in the world and Sunshine
Biopharma is a small microcap biopharma company. The two genes
associated with aggressive forms of cancer are Her2 and Top2; Roche is
targeting Her2-Positive patients and Sunshine Biopharma is targeting
multidrug resistant Top2, which has no current effective drugs in the
market for patients.
Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (
OTCBB: SBFM)
recently noted in an interview with Investorideas.com “Herceptin® is an
excellent drug and is very effective in treating Her2-Positive breast
cancer patients. However, only about 25% of the breast cancer patients
are Her2-Positive. For the remaining 75%, Herceptin® does not work. This
is where our Adva-27a comes in.”
Sunshine Biopharma reported on July 11, 2011 that Adva-27a had
shown 16-fold more effectiveness against MCF-7/MDR Multidrug Resistant
Breast Cancer and announced on June 26 th results that Adva-27a is
significantly more effective at killing Multidrug Resistant Small-Cell
Lung Cancer cells than Etoposide, the current commonly used drug for
this type of cancer.
Adva-27a was designed and synthesized de novo in 2006. Patents
covering Adva-27a and derivatives have recently issued in the United
States and Europe and are pending in other countries around the world.
Sunshine Biopharma has announced collaborations with the State
University of New York at Binghamton and McGill University's Jewish
General Hospital in Montreal (Canada) focused on the development of
Adva-27a through clinical trials.
Herceptin® was developed originally by Genentech, starting with
research that dated back to the 1970's and Roche later signed a
licensing agreement in 1998 for exclusive marketing rights for Herceptin
outside of the United States. A few months later Herceptin received FDA
approval for use in women with breast cancer that overexpresses the
HER2 protein. Herceptin® was the first therapeutic antibody targeted to a
specific (HER2) cancer-related molecular marker to receive FDA
approval. Roche purchased Genentech in March 2009 for approximately
$46.8 billion.
The most recent development on Herceptin® was June this year when
Roche announced the FDA had approved Perjeta® (pertuzumab) in
combination with Herceptin® and docetaxel chemotherapy for the treatment
of people with Her2-positive metastatic breast cancer who have not
received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Herceptin® sales were over $5 billion in 2010 but Herceptin® begins to lose patent protection in world markets in 2014.
Herceptin® Worldwide Sales in 2009/10
Source:
http://www.evaluatepharma.com/
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the
research, development and commercialization of drugs for the treatment
of various forms of cancer. The Company's lead compound, Adva-27a
targets aggressive forms of cancer.
www.sunshinebiopharma.com
About Roche (SIX: RO, ROG; OTCQX: RHHBY):
Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in pharmaceuticals
and diagnostics. Roche is the world's largest biotech company with truly
differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro
diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes
management. Roche's personalized healthcare strategy aims at providing
medicines and diagnostic tools that enable tangible improvements in the
health, quality of life and survival of patients. In 2011, Roche had
over 80,000 employees worldwide and invested over 8 billion Swiss francs
in R&D. The Group posted sales of 42.5 billion Swiss francs.
Genentech, United States, is a wholly owned member of the Roche Group.
Roche has a majority stake in Chugai Pharmaceutical, Japan.
www.roche.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector,
including biotech and pharma stocks. Visit the biotech portal within
Investor Ideas:
www.biotechindustrystocks.com
Follow Investorideas.com on Twitter
http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to
buy
or sell products or securities. This site is currently compensated by
featured companies, news submissions and online advertising. Disclosure:
A third party on behalf of SBFM compensated Investorideas.com for news
release publishing and distribution: one hundred thousand 144 shares for
three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source -
www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/
Disclosure: The Investorideas.com is a third party publisher of news
and research Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent
research. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. This site is
currently compensated by featured companies, news submissions and online
advertising. Disclosure: A third party on behalf of SBFM compensates
Investorideas.com for news release publishing and distribution : one
hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
About BioMimetic Therapeutics
ABOUT Kallo, Inc. 
Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (
About InvestorIdeas.com: